First interchangeability study for an adalimumab biosimilar has begunJuly 31, 2017PsoriasisPsoriatic Arthritis
First IL-23 blocker, guselkumab, earns FDA approval for psoriasisJuly 13, 2017PsoriasisPsoriatic Arthritis
Early phase III data positive for adalimumab biosimilar, for both psoriasis and PsAJuly 1, 2017Psoriatic ArthritisPsoriasis
Infliximab biosimilar noninferior to originator in IBD – NOR-SWITCHMay 23, 2017Psoriatic ArthritisPsoriasis
Adalimumab outperforms methotrexate in treating severe pediatric plaque psoriasisMay 17, 2017PsoriasisPsoriatic Arthritis
Secukinumab beat etanercept in 52-week psoriasis quality of life analysisApril 9, 2017PsoriasisPsoriatic Arthritis
_web.jpg)
